Dissemin is shutting down on January 1st, 2025

Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 6(64), 2020

DOI: 10.1128/aac.00170-20

Links

Tools

Export citation

Search in Google Scholar

Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model

Journal article published in 2020 by Maria-Ioanna Beredaki, Panagiota-Christina Georgiou, Maria Siopi ORCID, Lamprini Kanioura, David Andes, Maiken Cavling Arendrup ORCID, Johan W. Mouton, Joseph Meletiadis
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

CLSI and EUCAST susceptibility breakpoints for voriconazole and Candida albicans differ by one dilution (≤0.125 and ≤0.06 mg/liter, respectively) whereas the epidemiological cutoff values for EUCAST (ECOFF) and CLSI (ECV) are the same (0.03 mg/liter). We therefore determined the pharmacokinetic/pharmacodynamic (PK/PD) breakpoints of voriconazole against C. albicans for both methodologies with an in vitro PK/PD model, which was validated using existing animal PK/PD data.